Volume | 339,339 |
|
|||||
News | - | ||||||
Day High | 1.94 | Low High |
|||||
Day Low | 1.7002 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sensei Biotherapeutics Inc | SNSE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.81 | 1.7002 | 1.94 | 1.81 | 1.84 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
904 | 339,339 | $ 1.83 | $ 620,529 | - | 0.51 - 1.94 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:19:25 | 4 | $ 1.87 | USD |
Sensei Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
45.63M | 25.07M | - | 0 | -34.1M | -1.36 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sensei Biotherapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SNSE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.05 | 1.94 | 0.9712 | 1.63 | 1,179,160 | 0.76 | 72.38% |
1 Month | 1.03 | 1.94 | 0.9101 | 1.53 | 358,437 | 0.78 | 75.73% |
3 Months | 0.81 | 1.94 | 0.74 | 1.37 | 173,374 | 1.00 | 123.46% |
6 Months | 0.7709 | 1.94 | 0.5524 | 1.20 | 108,319 | 1.04 | 134.79% |
1 Year | 1.63 | 1.94 | 0.51 | 1.15 | 69,897 | 0.18 | 11.04% |
3 Years | 11.34 | 15.12 | 0.51 | 4.16 | 82,746 | -9.53 | -84.04% |
5 Years | 24.70 | 26.38 | 0.51 | 6.55 | 92,692 | -22.89 | -92.67% |
Sensei Biotherapeutics Description
Sensei Biotherapeutics Inc is a clinical-stage immunotherapy company. It is engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. The company's ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused, and coordinated innate and adaptive immune response. |